In a first-of-its-kind study, a cohort of researchers, led by the University of Colorado Anschutz Medical Campus, evaluated the effects of state-level insulin out-of-pocket costs across states and payers and over time.
Dupixent gets closer to EU approval as the FDA delays its decision on COPD – Pharmaceutical Technology
Sanofi and Regeneron’s Dupixent is approved in five indications. including atopic dermatitis, and generated $11.3bn in 2023. Credit: Wildflower_macro via Shutterstock. Sanofi and Regeneron’s blockbuster